AGS/AAO Position Statement on Nicotinamide Use for Glaucoma Neuroprotection
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
AGS/AAO Position Statement on Nicotinamide Use for Glaucoma Neuroprotection
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Dr. Emily Schehlein discusses recent guidelines from the American Glaucoma Society and the American Academy of Ophthalmology on Nicotinamide use for glaucoma neuroprotection with lead author, Dr. Aakriti Garg Shukla. Published in Ophthalmology Glaucoma, “American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection”
American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection. Shukla, Aakriti Garg; Cioffi, George A.; John, Simon W.M; Wang, Qing; Liebmann, Jeffrey M. et al. Ophthalmology Glaucoma, Volume 8, Issue 2, 112 – 116.
Sign up for the next Ophthalmology Journal Virtual Club on August 27, 2025, at https://store.aao.org/ophthalmology-virtual-journal-club.html